WuXi to Build Third Manufacturing Plant in Philly

Source: Asian Scientist Magazine

Mar 19, 2015

China-based WuXi PharmaTech has announced construction of a new, 145,000-square-foot cGMP facility in Philadelphia, Pennyslvania, for the manufacture of cell therapy products.

The new facility will be WuXi's third cell therapy manufacturing facility in Philadelphia, when it becomes operational by mid-2016. It will provide single-source contract development and cGMP manufacturing capabilities to support the rapidly growing cellular therapeutic industry's unique requirements.

The new facility expands on WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility, as well as a 45,000-square-foot facility for the manufacturing of allogeneic and autologous cell-based therapeutics that is expected to be completed by mid-2015.

Read the Asian Scientist Magazine release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments